Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Iovance Biotherapeutics's total debt was $1.00M at Dec 31, 2024. For fiscal 2024 it was $1.00M, up 0.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.00M | 0.0% |
| FY2023 | Dec 31, 2023 | $1.00M | 0.0% |
| FY2022 | Dec 31, 2022 | $1.00M | 0.0% |
| FY2021 | Dec 31, 2021 | $1.00M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $1.00M | 0.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.00M | 0.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.00M | 0.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.00M | 0.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.00M | 0.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.00M | 0.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.00M | 0.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.00M | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.00M | 0.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.00M | 0.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.00M | 0.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.00M | 0.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $1.00M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.00M | – |
See a number that looks wrong?